Alnylam Pharmaceuticals (ALNY) PT Raised to $270 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $224.03 -1.43%
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
29 Buy, 12 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Goldman Sachs analyst Salveen Richter raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $270.00 (from $239.00) while maintaining a Buy rating.
You May Also Be Interested In
- Raymond James Reiterates Strong Buy Rating on Alnylam Pharmaceuticals (ALNY)
- Pinnacle Financial Partners (PNFP) PT Raised to $115 at DA Davidson
- Zymeworks (ZYME) PT Raised to $52 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
